On January 5, 2026, Bicycle Therapeutics' CFO sold shares amid mixed analyst views and strong earnings beat.

On January 5, 2026, Bicycle Therapeutics CFO Alethia Young sold 4,334 shares at $6.49 each, totaling $28,127.66, reducing her stake by 4.74% to 87,081 shares. This follows a prior sale of 3,289 shares on January 2. The company reported Q3 earnings with a loss of $0.85 per share, beating estimates by $0.24, and revenue of $11.73 million, above the $8.25 million forecast. The stock closed at $6.57 on January 6, with above-average trading volume. Analysts have a mixed outlook, with a consensus "Hold" rating and a $19.73 target price. Institutional investors own 86.15% of the company.